Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.

Published:1994-09 Issue:3 Volume:38 Page:213-219
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:British Journal of Clinical Pharmacology

Author:

Kuhn JM,Legrand A,Ruiz JM,Obach R,Ronzan J,Thomas F

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1994.tb04344.x/fullpdf

Reference43 articles.

1. Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin and digestive peptides in normal men;Sassolas;J clin Endocrinol Metab,1989

2. Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men;Weeke;J clin Endocrinol Metab,1975

3. Differential effects of somatostatin (SRIH) and a SRIH analogue, SMS 201-995, on the secretion of growth hormone and thyroid-stimulating hormone in man;Williams;J clin Endocrinol Metab,1988

4. Octreotide treatment of acromegaly. A randomized multicenter study;Ezzat;Ann Int Med,1992

5. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995;Lamberts;New Engl J Med,1985

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review;Biomedicines;2024-03-05

2. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers;Pituitary;2022-01-09

3. Cyclic peptide drugs approved in the last two decades (2001–2021);RSC Chemical Biology;2022

4. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly;Expert Review of Clinical Pharmacology;2021-11-08

5. A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide;Clinical Case Reports;2021-05